COMP <GO>
INCY vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
Incyte Corp. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: INCY 10
— MRK 5
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: INCY
LAST: $120.39 (+3.07%) • MKT CAP: $23.68B
roic
42.40%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INCY VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INCY | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.80% | 74.80% | +18.00 | INCY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 42.40% | 20.70% | +21.70 | INCY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 15.3x | -2.80 | INCY | /valuation <GO> |
| Free Cash Flow Yield | 4.99% | 3.42% | +1.57 | INCY | /fcf-yield <GO> |
| Operating Margin | 29.50% | 34.30% | -4.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 25.00% | 28.10% | -3.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 21.20% | 1.30% | +19.90 | INCY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.04 | 5.19 | +4.85 | INCY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | INCY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.5 | 56.9 | +0.65 | INCY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.92 | +0.09 | INCY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 15.5x | 18.4x | -2.90 | INCY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.68B | $361.02B | -$337.35B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INCY REV | MRK REV | INCY GROSS % | MRK GROSS % | INCY FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.14B | $65.01B | 92.8% | 74.8% | $1.18B | $12.36B |
| FY 2024 | $4.24B | $64.17B | 92.6% | 76.3% | $144.5M | $18.10B |
| FY 2023 | $3.70B | $60.12B | 44.0% | 44.0% | $330.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INCY // BETA 1.01
MRK // BETA 0.92